Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Daxor Corporation (Nasdaq: DXR) presented new findings from Duke University Medical Center regarding the efficacy of its BVA-100 blood test for advanced heart failure patients at the ISHLT Annual Meeting in April 2023. The studies indicated that BVA measures provided better insight into intravascular congestion, particularly in obese patients, compared to traditional assessment methods. Key findings highlighted that pressure-volume relationships were poorly correlated in obese heart failure patients. Additionally, the BVA test offered clearer distinctions between true anemia and hemodilution, significantly impacting treatment strategies. Jonathan Feldschuh, Chief Scientific Officer, emphasized the importance of accurate blood volume measurement for effective heart failure management, suggesting that BVA could lead to improved patient outcomes and reduced costs.
Daxor Corporation (Nasdaq: DXR) announced its participation in the MedAxiom CV Transforum Spring’23 Conference in Orlando, FL from April 20-22, 2023. The company will sponsor a session featuring expert users discussing blood volume analysis (BVA) and its integration into heart failure programs, highlighting its impact on hospital length of stay and readmissions. Notably, BVA has shown to reduce 30-day mortality by 82%, 1-year mortality by 86%, and 30-day readmissions by 56%. Daxor's BVA technology provides clinicians with 98% accurate data, aiding in optimizing treatment plans and improving patient outcomes while reducing costs. Daxor aims to enhance healthcare through innovative blood volume testing and has conducted over 60,000 tests across top U.S. hospitals.
Daxor Corporation (Nasdaq: DXR) will attend the 43rd International Society for Heart and Lung Transplant Annual Meeting from April 19-22 in Denver, CO, showcasing its blood volume analysis (BVA) technology. The company will present three new studies highlighting the efficacy of its BVA-100® blood test in managing advanced heart failure. These studies include topics on the relationship between blood volume measures and exercise performance and discrepancies in cardiopulmonary exercise performance due to anemia.
CEO Michael Feldschuh emphasized the significance of the meeting for raising awareness of Daxor's diagnostic tool, which provides 98% accurate data to tailor treatment strategies, ultimately improving patient outcomes while minimizing care costs.
Daxor Corporation (NASDAQ: DXR) announced that five new hospitals have adopted its BVA-100 blood volume diagnostic tool to enhance fluid management in heart failure patients as of Q1 2023. This expansion, involving key healthcare organizations in New Jersey, Virginia, Mississippi, and Florida, signals significant growth in blood volume analysis sales. The BVA test has demonstrated substantial benefits, including an 82% reduction in 30-day mortality and a 56% decrease in readmissions for heart failure patients. CEO Michael Feldschuh emphasizes the growing need for effective management solutions as the population of heart failure patients is projected to rise from six million to over eight million in the coming years.